Favipiravir 200 mg

Sancovir 200 mg (Favipiravir) is a broad-spectrum antiviral with in vitro activity against various viruses, including coronaviruses, approved for emergency use to treat mild and moderate COVID-19 cases.

Using favipiravir to treat patients with COVID-19 showed significant clinical outcomes including:

• Lower incidence of dyspnea.
• Suitable for concomitant use with corticosteroids.
• Shorter viral clearance.
• Improvement in chest imaging.
• Well-tolerated treatment.
• Better treatment effects on disease progression.
• Faster relief for cough and pyrexia.
• Suitable for use at home.